Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 3

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 1
Chunk 3
---
000  
     320,117 
  
    Stock-based inducement expense 
     -  
     -  
     (863,550) 
     -  
     - 
  
    Write off of deferred offering costs 
     (500,000) 
     -  
     (500,000) 
     -  
     - 
  
    Interest income (expense), net 
     5,936  
     4,418  
     20,562  
     (26,993) 
     4,805 

    Total other income (expenses), net 
     (493,816) 
     174,271  
     (1,342,740) 
     4,801,308  
     324,922 
  
    Net loss 
     (4,856,395) 
     (4,227,967) 
     (15,379,641) 
     (8,404,104) 
     (572,211)
  
    Deemed dividend on Series A, B and C Preferred Stock 
     -  
     -  
     (24,964,518) 
     -  
     - 
  
    Deemed dividend on Series D Preferred Stock 
     (6,649,828) 
     -  
     (6,649,828) 
     -  
     - 
  
    Deemed dividend related to Series C Common Warrants 
     -  
     -  
     (84,083) 
     -  
     - 
  
    Net loss attributable to common shareholders 
    $(11,506,223) 
    $(4,227,967) 
    $(47,078,070) 
    $(8,404,104) 
    $(572,211)

    Net loss per common share: 

    Basic and diluted 
    $(9.10) 
    $(170.22) 
    $(72.94) 
    $(560.27) 
    $(1,959.63)
  
    Weighted average common shares outstanding: 

    Basic and diluted 
     1,264,884  
     24,838  
     645,452  
     15,000  
     292 

See